$LYEL

Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4M - News and Statistics

Lyell Immunopharma reported a net loss of $140.7 million for the final quarter of 2025, with revenue totaling $6,000. For the full fiscal year 2025, the company announced an annual net loss of $274.4 million and annual revenue of $36,000. This financial update includes a comprehensive report on the antisera industry in the United States, detailing market dynamics, trade flows, and forecasts to 2035.

Original reporting
Published Mar 13, 2026, 10:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 13, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4M - News and Statistics — source image
Decision brief

The 30-second read

$LYELBearishLow
01

Why it matters

The significant losses may lead to short-term negative sentiment, but long-term investors might interpret this as a phase of strategic investment.

02

Market read

The news has limited immediate impact on the broader biotech sector but is relevant for investors holding LYEL shares.

03

What to watch

Potential upcoming product launches or strategic partnerships not reflected in current financials could alter the company's outlook.

Timing: long-term

Background

Lyell Immunopharma is a biotech firm focusing on cell therapy technologies. The 2025 financial results reveal ongoing operational challenges.

Company-level read

Ticker impact

$LYELBearishMedium confidence
Context

Lyell Immunopharma's 2025 financial results indicate significant losses, which may influence investor sentiment and stock valuation.

Expected impact

Potential short-term decline in LYEL stock price due to poor financial results, followed by possible stabilization if company implements strategic changes.

Evidence & confidence

Financial losses are significant, but limited revenue and low relevance score suggest limited immediate impact; long-term effects depend on future operational improvements.

Market effects

The report highlights ongoing challenges in the biotech and life sciences sectors, which may lead to cautious investor sentiment across related stocks.

Limited regional impact, as the company's operations are primarily US-focused and the financial results are specific to Lyell Immunopharma.

Low, given the company's size and the specificity of the financial results.

Counterpoint

The company's losses may be part of a strategic investment phase, and stock prices could rebound if future developments are positive.

Key entities

  • Lyell Immunopharma

    A biotechnology company specializing in cell therapy.

Related articles

$LYELMed

Lyell Immunopharma, Inc. (LYEL): Results of Operations and Financial Condition

Lyell Immunopharma, Inc. (LYEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lyel-20260806x8kexx991.htm EX-99.1 Document Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 • PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data i

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.